<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04206293</url>
  </required_header>
  <id_info>
    <org_study_id>CMO-MA-FAS-0617</org_study_id>
    <nct_id>NCT04206293</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate The Impact on Skin Quality Attributes by Juvederm® Volite Injection on Healthy Volunteers</brief_title>
  <official_title>Prospective, Open-Label Study, to Evaluate The Impact on Skin Quality Attributes by Juvederm® Volite Injection on Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the impact on skin quality attributes, including physical measurements and gene
      and protein expression (histological and genomic analysis), following administration of
      Juvéderm® VOLITE in the volar forearms of healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 29, 2019</start_date>
  <completion_date type="Anticipated">July 25, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 25, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Skin Hydration</measure>
    <time_frame>Baseline, 1 and 3 months after HA injection in the forearm</time_frame>
    <description>MoistureMeter D® 0.5 mm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Skin Hydration</measure>
    <time_frame>Baseline, 1 and 3 months after HA injection in the forearm</time_frame>
    <description>MoistureMeter D® 1.5mm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Skin Hydration</measure>
    <time_frame>Baseline, 1 and 3 months after HA injection in the forearm</time_frame>
    <description>Corneometer®</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Skin Elasticity</measure>
    <time_frame>Baseline, 1 and 3 months after HA injection in the forearm</time_frame>
    <description>Cutometer®</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Skin Elasticity</measure>
    <time_frame>Baseline, 1 and 3 months after HA injection in the forearm</time_frame>
    <description>Elastimeter®</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Skin Thickness and Density</measure>
    <time_frame>Baseline, 1 and 3 months after HA injection in the forearm</time_frame>
    <description>Skin Scanner®</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Skin Roughness, Density, and Vascularity</measure>
    <time_frame>Baseline, 1 and 3 months after HA injection in the forearm</time_frame>
    <description>Vivosight OCT®</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Skin Brightness</measure>
    <time_frame>Baseline, 1 and 3 months after HA injection in the forearm</time_frame>
    <description>Glossymeter®</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Skin Color</measure>
    <time_frame>Baseline, 1 and 3 months after HA injection in the forearm</time_frame>
    <description>Spectrophotometer®</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Skin Melanin Content</measure>
    <time_frame>Baseline, 1 and 3 months after HA injection in the forearm</time_frame>
    <description>Mexameter®</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Histological and Genomic Analysis</measure>
    <time_frame>1 and 3 months after HA injection in forearm</time_frame>
    <description>Cutaneous Biopsy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Healthy Adults</condition>
  <condition>Skin Enhancement</condition>
  <arm_group>
    <arm_group_label>Intradermal Injection - Volar left forearm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment zone</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hyaluronic acid (HA) intradermal injection in the forearm</intervention_name>
    <description>Treatment zone</description>
    <arm_group_label>Intradermal Injection - Volar left forearm</arm_group_label>
    <other_name>Juvederm® VOLITE</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subject

          -  Subjects with Fitzpatrick skin type II or III

          -  Subject willing to receive Juvéderm® VOLITE in the forearms and agrees to complete all
             study required procedures, including having 6 cutaneous punch biopsies taken in the
             forearms and blood drawn (HIV, B and C hepatitis analysis at screening)

          -  Written informed consent and data privacy consent obtained

        Exclusion Criteria:

          -  Pregnant or nursing woman or planning a pregnancy during the study

          -  Subject participating to another research on human beings or being in an exclusion
             period for a previous study

          -  Intensive exposure to sunlight or UV-rays within the previous month and foreseen
             during the study

          -  Subject having other resorbable filling product injections, a laser treatment, an
             ultrasound-based treatment, radiation treatment, a dermabrasion, a surgery, a deep
             chemical peeling or other ablative procedure on the studied zones within the past 12
             months prior to study start

          -  Subject with subcutaneous retaining structure on the studied zones (meshing, threads,
             gold strand)

          -  Subject having received injections of permanent or semi-permanent filling products in
             the studied zones

          -  Subject under anti-coagulant treatment or treatment liable to interfere with the
             healing process or hemostasis, during the previous month and during the study

          -  Subject receiving or is planning to receive anti-inflammatory drugs (oral/injectable
             corticosteroids or NSAIDs, e.g., aspirin, ibuprofen), or other substances known to
             increase coagulation time (herbal supplements with garlic or ginkgo biloba, etc) for
             10 days prior to study treatment and 3 days after

          -  Subject under immunosuppressive therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charlie Hee</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>EuroFins Dermscan Poland</name>
      <address>
        <city>Gdansk</city>
        <zip>80288</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <link>
    <url>http://www.AllerganClinicalTrials.com</url>
    <description>Additional information on study locations near you may be found at AllerganClinicalTrials.com.</description>
  </link>
  <link>
    <url>http://www.investigatordatabank.org/</url>
    <description>To be considered as a site for current and future Allergan Clinical Trials, please register using the Investigator Databank link.</description>
  </link>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 18, 2019</study_first_submitted>
  <study_first_submitted_qc>December 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 20, 2019</study_first_posted>
  <last_update_submitted>January 27, 2020</last_update_submitted>
  <last_update_submitted_qc>January 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

